SCHEMBL3628641

SCHEMBL3628641

[CH2]CCCN1CCC(c2ccccc2)(c2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 1/20 0.53
HTR7 P34969 1/20 0.50
SIGMAR1 Q99720 2/20 0.49
OPRM1 P35372 3/20 0.47
DRD4 P21917 1/20 0.47
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
GRIN1 Q05586 1/20 0.46
KCNH2 Q12809 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
CYP2D6 P10635 1/20 0.46
DRD2 P14416 1/20 0.44
TSHR P16473 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
CCR1 P32246 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6956108 0.89 OPRM1 (0.50) ADRA1AHTR7SIGMAR1OPRM1DRD4
SCHEMBL6195779 0.84 SIGMAR1 (0.57) ADRA1AHTR7SIGMAR1OPRM1DRD4
SCHEMBL7031418 0.83 TSHR (0.62) ADRA1AHTR7SIGMAR1OPRM1DRD4
SCHEMBL5729369 0.83 SIGMAR1 (0.58) ADRA1AHTR7SIGMAR1OPRM1CYP2D6
SCHEMBL7959903 0.83 ADRA1A (0.53) ADRA1AHTR7SIGMAR1OPRM1DRD4
SCHEMBL11740559 0.83 ADRA1A (0.57) ADRA1AHTR7SIGMAR1OPRM1DRD4
SCHEMBL9382710 0.81 TSHR (0.56) ADRA1AHTR7SIGMAR1OPRM1DRD4
SCHEMBL11744408 0.81 OPRM1 (0.56) ADRA1AHTR7SIGMAR1OPRM1DRD4
SCHEMBL7243212 0.80 OPRM1 (0.52) ADRA1AHTR7SIGMAR1OPRM1DRD4
SCHEMBL11747588 0.80 OPRM1 (0.59) ADRA1AHTR7SIGMAR1OPRM1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487444-B9 USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS ASTELLAS DEUTSCHLAND GMBH (DE) 2010-07-21 EP claimed
EP-1487444-B1 USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS ASTELLAS DEUTSCHLAND GMBH (DE) 2009-12-30 EP claimed
US-20060052419-A1 Use of pyridly amides as inhibitors of angiogenesis ASTELLAS DEUTSCHLAND GMBH (DE) 2006-03-09 US claimed
EP-1348434-A1 Use of pyridyl amides as inhibitors of angiogenesis Fujisawa Deutschland GmbH (DE) 2003-10-01 EP claimed
EP-1487444-B9 USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS ASTELLAS DEUTSCHLAND GMBH (DE) 2010-07-21 EP disclosed
EP-1487444-B1 USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS ASTELLAS DEUTSCHLAND GMBH (DE) 2009-12-30 EP disclosed
US-20060052419-A1 Use of pyridly amides as inhibitors of angiogenesis ASTELLAS DEUTSCHLAND GMBH (DE) 2006-03-09 US disclosed
EP-1348434-A1 Use of pyridyl amides as inhibitors of angiogenesis Fujisawa Deutschland GmbH (DE) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052419-A1 Use of pyridly amides as inhibitors of angiogenesis FLT1, VEGFA, FLT4 ADRA1A 1052/4885HTR7 1985/4885SIGMAR1 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.